Valeritas (NSDQ:VLRX) said today that its wearable insulin delivery device, V-Go, won preferred status on the OptumRx formulary.
The Bridgewater, N.J.-based company’s device is designed for people with Type 2 diabetes. The V-Go product is worn like a patch and delivers a preset basal rate of insulin over the course of 24 hours. The device can also deliver on-demand bolus dosing at mealtimes.
Valeritas reported that its V-Go product is available as ‘preferred’ on the OptumRx Select, OptumRx Premium and OptumRx Core formularies.
“We are very excited that V-Go is now Preferred on OptumRx formularies,” CEO John Timberlake said in prepared remarks. “V-Go helps patients simplify their insulin therapy and improve their management of diabetes. With this decision to make V-Go Preferred by OptumRx, V-Go should be even more affordable for many patients with type 2 diabetes.”
Earlier this month, the company’s device won preferred status on Humana’s Part D formularies.
